Patent US2501772A successfully refreshed from Google Patents.
Patent US2742476A successfully refreshed from Google Patents.
Patent US4404183A successfully refreshed from Google Patents.
US4404183A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Sustained release pharmaceutical composition of solid medical material
Assignee: Astellas Pharma Inc
•
Filing: 1982-07-29
•
Granted: 1983-09-13
•
Expires: 2002-07-29
Abstract
Abstract Sustained release pharmaceutical compositions of a solid medical material which contains an amorphous solid medical material, polyethylene oxide, and at least one basic substance selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl pyrrolidone, carboxyvinyl polymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, methyl meta-acrylate meta-acrylic acid copolymer, polyvinylacetal diethylaminoacetate, dimethylaminoethyl meta-acrylate meta-acrylic acid copolymer, 2-methyl-5-vinylpyridinemethyl acrylate meta-acrylic acid copolymer, citric acid, urea, succinic acid and amino acid, and may further contain one basic substance selected from the group consisting of a surface active agent, polyethylene glycol, propylene glycol, glycerin, a glycerin fatty acid ester and a vegetable oil (first embodiment); and in the case where the solid medical material is nicardipine, the composition may consist only of the amorphous nicardipine or a salt thereof without the above compound (second embodiment).
Inventors
- 👤 Hiroitsu Kawata
- 👤 Masayoshi Aruga
- 👤 Tadayoshi Ohmura
- 👤 Takashi Sonobe
- 👤 Satoru Yoneya
- 👤 Chiharu Sone
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 14:23
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/14; A61K9/141; A61K9/146; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61K9/16; A61K9/1605; A61K9/1611
Claims Analysis
Total Claims: 10
Claim 1
Independent Claim
33 words
A sustained release pharmaceutical composition comprising an effective amount of an amorphous form of indomethacin or a salt thereof, and polyethylene oxide in the form of a fine powder or fine particle granules.
Claim 2
Dependent Claim
33 words
A sustained release pharmaceutical composition comprising an effective amount of an amorphous form of indomethacin or a salt thereof, and polyethylene oxide in the form of a fine powder or fine particle granules.
Claim 3
Dependent Claim
78 words
A pharmaceutical composition as claimed in claim 1 which contains (i) amorphous indomethacin or a salt thereof, (ii) said polyethylene oxide and (iii) at least one basic substance (1st component) selected from the group consisting of hydroxypropylmethyl cellulose, hydroxypropyl cellulose, methyl cellulose, polyvinyl pyrrolidone, carboxyvinyl polymer, hydroxypropylmethyl cellulose phthalate, cellulose acetate phthalate, methyl meta-acrylate meta-acrylic acid copolymer, polyvinylacetal diethylaminoacetate, dimethylaminoethyl meta-acrylate meta-acrylic acid copolymer, 2-methyl-5-vinylpyridinemethyl acrylate meta-acrylic acid copolymer, citric acid, urea, succinic acid and an amino acid.
Claim 4
Dependent Claim
57 words
A pharmaceutical composition as claimed in claim 1 which contains (i) an amorphous indomethacin or a salt thereof, (ii) said polyethylene oxide, (iii) said 1st component(s) and at least one basic substance (2nd component) selected from the group consisting of a surface active agent, polyethylene glycol, propylene glycol, glycerine, glycerine fatty acid ester and a vegetable oil.
Claim 5
Dependent Claim
30 words
A process of producing a sustained release pharmaceutical composition as claimed in claim 1 characterized by compounding said indomethacin or a salt thereof in amorphous form with said polyethylene oxide.
Claim 6
Dependent Claim
42 words
The process of producing a sustained release pharmaceutical composition as claimed in claim 2 which comprises dissolving indomethacin or a salt thereof and said 1st component(s), in water or an organic solvent, distilling off the solvent, and then adding said polyethylene oxide.
Claim 7
Dependent Claim
46 words
The process of producing a sustained release pharmaceutical composition as claimed in claim 3 which comprises dissolving said indomethacin or a salt thereof, said 1st component(s) and said 2nd component(s), in water or an organic solvent, distilling off the solvent, and then adding said polyethylene oxide.
Claim 8
Dependent Claim
42 words
The process of producing a sustained release pharmaceutical composition as claimed in claim 2 which comprises dissolving said indomethacin or a salt thereof, said 1st component(s) and said polyethylene oxide, in water or an organic solvent, and then distilling off the solvent.
Claim 9
Dependent Claim
44 words
The process of producing a sustained release pharmaceutical composition as claimed in claim 3 which comprises dissolving said indomethacin or a salt thereof, said 1st components(s), said 2nd component(s) and said polyethylene oxide in water or an organic solvent, and distilling off the solvent.
Claim 10
Dependent Claim
19 words
The composition as claimed in claim 1, wherein said indomethacin is in the form of an amorphous indomethacin base.
References Cited (Backward Citations)
US2149005A
Cited
US2540253A
Cited
US2698822A
Cited
US3325362A
Cited
US3297804A
Cited
US3308217A
Cited
US3670065A
Cited
US3634584A
Cited
US3862311A
Cited
US4151273A
Cited
US4343789A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1986-09-12 | 1987-03-14 | 1987-09-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1990-09-12 | 1991-03-14 | 1991-09-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1994-09-12 | 1995-03-14 | 1995-09-13 | $7700.00 | Window Closed / Lapsed |